Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy
- PMID: 12712058
- DOI: 10.1067/mpd.2003.139
Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy
Abstract
Objective: To compare the structural growth and developmental outcome of children born to mothers diagnosed with major depressive disorder during pregnancy who were exposed or not exposed to selective serotonin reuptake inhibitors (SSRIs) in utero.
Study design: Children whose mothers were diagnosed with major depressive disorder in pregnancy and elected not to take medication (n = 13) were compared with children of depressed mothers treated with SSRIs (n = 31) on birth outcomes and postnatal neurodevelopmental functioning between ages 6 and 40 months. Children underwent blinded standardized pediatric and dysmorphology examinations and evaluations of their mental and psychomotor development with the use of the Bayley Scales of Infant Development (BSID II).
Results: The Bayley mental developmental indexes were similar in both groups. Children exposed to SSRIs during pregnancy had lower APGAR scores and scored lower on the Bayley psychomotor development indexes and the motor quality factor of the Bayley Behavioral Rating Scale than unexposed children.
Conclusions: The findings that SSRIs during fetal development might have subtle effects on motor development and motor control are consistent with the pharmacologic properties of the drugs.
Similar articles
-
Variations in Neurodevelopmental Outcomes in Children with Prenatal SSRI Antidepressant Exposure.Birth Defects Res. 2017 Jul 17;109(12):909-923. doi: 10.1002/bdr2.1076. Birth Defects Res. 2017. PMID: 28714603 Review.
-
Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data.BMJ Open. 2016 Nov 29;6(11):e013293. doi: 10.1136/bmjopen-2016-013293. BMJ Open. 2016. PMID: 27899401 Free PMC article.
-
Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.Am J Psychiatry. 2012 Nov;169(11):1165-74. doi: 10.1176/appi.ajp.2012.11111721. Am J Psychiatry. 2012. PMID: 23128923
-
Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.Psychopharmacology (Berl). 2011 Sep;217(2):211-9. doi: 10.1007/s00213-011-2270-z. Epub 2011 Apr 16. Psychopharmacology (Berl). 2011. PMID: 21499702
-
[Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].Encephale. 2010 Jun;36 Suppl 2:D133-8. doi: 10.1016/j.encep.2009.06.005. Epub 2009 Sep 19. Encephale. 2010. PMID: 20513456 Review. French.
Cited by
-
Brain structural and functional outcomes in the offspring of women experiencing psychological distress during pregnancy.Mol Psychiatry. 2024 Feb 28. doi: 10.1038/s41380-024-02449-0. Online ahead of print. Mol Psychiatry. 2024. PMID: 38418579 Review.
-
Antidepressants use during pregnancy and child psychomotor, cognitive and language development at 2 years of age-Results from the 3D Cohort Study.Front Pharmacol. 2023 Nov 16;14:1252251. doi: 10.3389/fphar.2023.1252251. eCollection 2023. Front Pharmacol. 2023. PMID: 38035027 Free PMC article.
-
Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders.Int J Environ Res Public Health. 2023 Aug 11;20(16):6565. doi: 10.3390/ijerph20166565. Int J Environ Res Public Health. 2023. PMID: 37623151 Free PMC article.
-
Development of the Placenta and Brain Are Affected by Selective Serotonin Reuptake Inhibitor Exposure During Critical Periods.Adv Exp Med Biol. 2023;1428:179-198. doi: 10.1007/978-3-031-32554-0_8. Adv Exp Med Biol. 2023. PMID: 37466774 Review.
-
Prenatal SSRI Exposure Increases the Risk of Autism in Rodents via Aggravated Oxidative Stress and Neurochemical Changes in the Brain.Metabolites. 2023 Feb 20;13(2):310. doi: 10.3390/metabo13020310. Metabolites. 2023. PMID: 36837929 Free PMC article.
